Siolta Therapeutics develops therapies through understanding of human microbial ecology. The company combines clinical data, bioinformatics, and microbial science to develop combinations of bacteria that target disease-specific mechanisms of action.

Siolta Therapeutics

Siolta Therapeutics is a clinical-stage biotech company developing live biotherapeutics to improve outcomes in conditions with unmet medical needs. Our offices and laboratory are located in San Carlos, CA.  

National Institute of Allergy and Infectious Diseases

Seventure Partners

Global Brain Corporation

Khosla Ventures

SymBiosis LLC

Marc Benioff

Thanks @Ilana Golant @foodallergyfund – I’m excited to join an amazing group of folks elevating the conversation on food allergies! The Annual Food Allergy Fund Summit, held in New York City on May 23rd, will highlight the latest advancements and cutting-edge developments in food allergy research and innovation. 

Check out the agenda and support the cause here: https://lnkd.in/gs2tzeKu

Looking forward to supporting industry-academia cross-pollination at the Joint Berkeley Initiative for Microbiome Science (JBIMS) next week on May 9th from 2:00 PM to 6:00 PM at the Bakar BioEngenuity Hub at UC Berkeley.

This event aims to strengthen ties between leading microbiome researchers from academia and dynamic industry players. RSVP here: https://lnkd.in/gXH85Uxe 

Thanks to Eoin Brodie, Britt Koskella, and Matt Traxler for keeping us all connected!

Thanks to all of you supporting our vision of a better world where our healthcare, including drug development, is focused on solutions that alleviate disease from the start!

Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development

https://lnkd.in/gzStYAHg

COM:SIOLTATHERAPEUTICS

Siolta Therapeutics

Financials Not Available